Geode Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $10.3M | Buy |
1,069,927
+53,504
| +5% | +$513K | ﹤0.01% | 2348 |
|
2025
Q1 | $6.37M | Sell |
1,016,423
-2,072
| -0.2% | -$13K | ﹤0.01% | 2538 |
|
2024
Q4 | $8.27M | Buy |
1,018,495
+155,577
| +18% | +$1.26M | ﹤0.01% | 2480 |
|
2024
Q3 | $15.6M | Buy |
862,918
+56,871
| +7% | +$1.03M | ﹤0.01% | 2120 |
|
2024
Q2 | $8.3M | Buy |
806,047
+54,668
| +7% | +$563K | ﹤0.01% | 2441 |
|
2024
Q1 | $7.98M | Buy |
751,379
+16,106
| +2% | +$171K | ﹤0.01% | 2456 |
|
2023
Q4 | $6.71M | Buy |
735,273
+52,703
| +8% | +$481K | ﹤0.01% | 2553 |
|
2023
Q3 | $7.08M | Buy |
682,570
+192,447
| +39% | +$2M | ﹤0.01% | 2460 |
|
2023
Q2 | $7.02M | Buy |
490,123
+41,512
| +9% | +$594K | ﹤0.01% | 2507 |
|
2023
Q1 | $3.2M | Buy |
448,611
+13,567
| +3% | +$96.9K | ﹤0.01% | 2827 |
|
2022
Q4 | $4.88M | Buy |
435,044
+32,752
| +8% | +$367K | ﹤0.01% | 2681 |
|
2022
Q3 | $4.46M | Buy |
402,292
+55,356
| +16% | +$613K | ﹤0.01% | 2741 |
|
2022
Q2 | $2.93M | Buy |
346,936
+33,119
| +11% | +$280K | ﹤0.01% | 2978 |
|
2022
Q1 | $4.27M | Buy |
313,817
+20,619
| +7% | +$281K | ﹤0.01% | 2886 |
|
2021
Q4 | $5.77M | Buy |
293,198
+9,335
| +3% | +$184K | ﹤0.01% | 2819 |
|
2021
Q3 | $9.11M | Buy |
283,863
+2,490
| +0.9% | +$79.9K | ﹤0.01% | 2515 |
|
2021
Q2 | $9.52M | Buy |
281,373
+71,865
| +34% | +$2.43M | ﹤0.01% | 2491 |
|
2021
Q1 | $7.87M | Buy |
209,508
+32,034
| +18% | +$1.2M | ﹤0.01% | 2519 |
|
2020
Q4 | $5.9M | Sell |
177,474
-4,125
| -2% | -$137K | ﹤0.01% | 2515 |
|
2020
Q3 | $6.66M | Buy |
181,599
+3,257
| +2% | +$119K | ﹤0.01% | 2226 |
|
2020
Q2 | $5.87M | Buy |
178,342
+17,415
| +11% | +$573K | ﹤0.01% | 2240 |
|
2020
Q1 | $4.16M | Buy |
160,927
+7,493
| +5% | +$193K | ﹤0.01% | 2246 |
|
2019
Q4 | $4.78M | Buy |
+153,434
| New | +$4.78M | ﹤0.01% | 2485 |
|